Notice Information
Notice Title
Whole Genome Sequencing (WGS) Long Read Instruments & Consumables
Notice Description
The supply of instruments and consumables that provides a solution to enable investigations into methylation (5mC,5hmC), structural variant calling, copy number variant analysis and single nucleotide polymorphisms (SNP) detection.
Lot Information
Lot 1
Genomics England continues to explore long-read and methylation sequencing in cancer within the NHS and accurately to sequence genomes of under-represented and diverse ancestries with a view that this novel technology could open opportunities to identify not only known genomic features and aberrations but also those that are currently unidentifiable using existing sequencing technologies. This could facilitate immediate returns in diagnostic value to the NHS and reaping more meaningful rewards in the near future through more thorough analysis of the whole genome. Long-read analytical methods are still in their infancy, Genomics England is building a knowledge hub around the trusted research environment for individuals to train their methods; in turn these methods feed into the clinical pipeline of the future. Nurturing the research environment will permit the discovery of new diagnostic and prognostic markers as well as potential new targets for drug discovery to benefit patients in the future. Genomics England has a requirement to continue to purchase Long Read sequencing technology to fulfil its needs in relation to its Cancer Programme, Diverse Data Programme and Newborns Long Read sequencing initiative. The requirement is to provide sufficient consumables to meet the forecasts for remainder of FY24/25 and to fulfull the program outcomes. This relates to an initial purchase of 3900 flow cells and associated consumables, with the option to purchase a further 4400 flow cells and associated consumables for the programmed described above. The requirement relates to continuing to purchase Oxford Nanopore Technologies (ONT) PromethION Flowcells to continue the studies using the same technology.
Options: Genomics England can exercise an option to purchase up to an additional 4,400 flow cells and associated consumables at a cost of up to PS2,774,772 under this notice.
Procurement Information
The Contracting Authority (i) has a legal personality; (ii) is mainly funded by the Department of Health and Social Care; and (iii) has been established for the specific purpose of meeting needs in the general interest and does not have an industrial or commercial character and therefore meets the definition of a "body governed by public law" under the Public Contracts Regulations 2015 ("PCR"). The PCR covers "public contracts" which means contracts for pecuniary interest which have as their object the execution of works, the supply of products or the provision of services. The Contract is a goods or services contract under PCR, therefore, caught by the PCR and bound to follow public procurement rules. Regulation 32(2)(b)(ii) PCR describes the single operator exclusion and is the premise for this award without prior publication. This specific exclusion relates to a demonstration that only Oxford Nanopore Technologies PLC could deliver the goods and services described for technical reasons and reasons of scalability, where the goods and services cannot be obtained from any other economic operator to continue to deliver the programme using the same long read whole genome sequencing technology. The scope of requirements in this notice are the basis for this assessment. For technical reasons, it has been determined that Oxford Nanopore Technologies PLC are the only provider able to meet the justified requirements set out. Furthermore, they are also the only organisation able to deliver the requirement at the scale specified. Further details are provided within this notice and should be read in conjunction with this explanation. The Contracting Authority will enter into a contract with Oxford Nanopore Technologies Limited following the conclusion of a minimum 10-day standstill period from the date of issue of this notice. The 10-day standstill period will end on Monday 16th December 2024 at 11.59pm GMT, enabling a contract to be signed from Tuesday 17th December 2024.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-04c569
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/039504-2024
- Current Stage
- Award
- All Stages
- Award
Procurement Classification
- Notice Type
- Award Notice
- Procurement Type
- Standard
- Procurement Category
- Goods
- Procurement Method
- Limited
- Procurement Method Details
- Negotiated without publication of a contract notice
- Tender Suitability
- Not specified
- Awardee Scale
- Large
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
-
- CPV Codes
33140000 - Medical consumables
33190000 - Miscellaneous medical devices and products
33696200 - Blood-testing reagents
33696500 - Laboratory reagents
Notice Value(s)
- Tender Value
- Not specified
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- £5,234,229 £1M-£10M
Notice Dates
- Publication Date
- 6 Dec 20241 years ago
- Submission Deadline
- Not specified
- Future Notice Date
- Not specified
- Award Date
- 6 Dec 20241 years ago
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Not Specified
- Awards Status
- Active
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- GENOMICS ENGLAND
- Contact Name
- Paul Nicholson
- Contact Email
- paul.nicholson@genomicsengland.co.uk
- Contact Phone
- +44 2078825030
Buyer Location
- Locality
- LONDON
- Postcode
- E14 5AB
- Post Town
- East London
- Country
- England
-
- Major Region (ITL 1)
- TLI London
- Basic Region (ITL 2)
- TLI4 Inner London - East
- Small Region (ITL 3)
- TLI42 Tower Hamlets
- Delivery Location
- TLI London
-
- Local Authority
- Tower Hamlets
- Electoral Ward
- Canary Wharf
- Westminster Constituency
- Poplar and Limehouse
Further Information
Notice URLs
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-04c569-2024-12-06T17:12:20Z",
"date": "2024-12-06T17:12:20Z",
"ocid": "ocds-h6vhtk-04c569",
"initiationType": "tender",
"tender": {
"id": "GEL-SR-291-21-004",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "Whole Genome Sequencing (WGS) Long Read Instruments & Consumables",
"status": "complete",
"classification": {
"scheme": "CPV",
"id": "33696500",
"description": "Laboratory reagents"
},
"mainProcurementCategory": "goods",
"description": "The supply of instruments and consumables that provides a solution to enable investigations into methylation (5mC,5hmC), structural variant calling, copy number variant analysis and single nucleotide polymorphisms (SNP) detection.",
"lots": [
{
"id": "1",
"description": "Genomics England continues to explore long-read and methylation sequencing in cancer within the NHS and accurately to sequence genomes of under-represented and diverse ancestries with a view that this novel technology could open opportunities to identify not only known genomic features and aberrations but also those that are currently unidentifiable using existing sequencing technologies. This could facilitate immediate returns in diagnostic value to the NHS and reaping more meaningful rewards in the near future through more thorough analysis of the whole genome. Long-read analytical methods are still in their infancy, Genomics England is building a knowledge hub around the trusted research environment for individuals to train their methods; in turn these methods feed into the clinical pipeline of the future. Nurturing the research environment will permit the discovery of new diagnostic and prognostic markers as well as potential new targets for drug discovery to benefit patients in the future. Genomics England has a requirement to continue to purchase Long Read sequencing technology to fulfil its needs in relation to its Cancer Programme, Diverse Data Programme and Newborns Long Read sequencing initiative. The requirement is to provide sufficient consumables to meet the forecasts for remainder of FY24/25 and to fulfull the program outcomes. This relates to an initial purchase of 3900 flow cells and associated consumables, with the option to purchase a further 4400 flow cells and associated consumables for the programmed described above. The requirement relates to continuing to purchase Oxford Nanopore Technologies (ONT) PromethION Flowcells to continue the studies using the same technology.",
"hasOptions": true,
"options": {
"description": "Genomics England can exercise an option to purchase up to an additional 4,400 flow cells and associated consumables at a cost of up to PS2,774,772 under this notice."
}
}
],
"items": [
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33140000",
"description": "Medical consumables"
},
{
"scheme": "CPV",
"id": "33190000",
"description": "Miscellaneous medical devices and products"
},
{
"scheme": "CPV",
"id": "33696200",
"description": "Blood-testing reagents"
}
],
"deliveryAddresses": [
{
"region": "UKI"
}
],
"relatedLot": "1"
}
],
"procurementMethod": "limited",
"procurementMethodDetails": "Negotiated without publication of a contract notice",
"coveredBy": [
"GPA"
],
"procurementMethodRationaleClassifications": [
{
"scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
"id": "D_MANUF_FOR_RESEARCH",
"description": "The products involved are manufactured purely for the purpose of research, experiment, study or development under the conditions stated in the directive"
},
{
"scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
"id": "D_TECHNICAL",
"description": "The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons"
}
],
"procurementMethodRationale": "The Contracting Authority (i) has a legal personality; (ii) is mainly funded by the Department of Health and Social Care; and (iii) has been established for the specific purpose of meeting needs in the general interest and does not have an industrial or commercial character and therefore meets the definition of a \"body governed by public law\" under the Public Contracts Regulations 2015 (\"PCR\"). The PCR covers \"public contracts\" which means contracts for pecuniary interest which have as their object the execution of works, the supply of products or the provision of services. The Contract is a goods or services contract under PCR, therefore, caught by the PCR and bound to follow public procurement rules. Regulation 32(2)(b)(ii) PCR describes the single operator exclusion and is the premise for this award without prior publication. This specific exclusion relates to a demonstration that only Oxford Nanopore Technologies PLC could deliver the goods and services described for technical reasons and reasons of scalability, where the goods and services cannot be obtained from any other economic operator to continue to deliver the programme using the same long read whole genome sequencing technology. The scope of requirements in this notice are the basis for this assessment. For technical reasons, it has been determined that Oxford Nanopore Technologies PLC are the only provider able to meet the justified requirements set out. Furthermore, they are also the only organisation able to deliver the requirement at the scale specified. Further details are provided within this notice and should be read in conjunction with this explanation. The Contracting Authority will enter into a contract with Oxford Nanopore Technologies Limited following the conclusion of a minimum 10-day standstill period from the date of issue of this notice. The 10-day standstill period will end on Monday 16th December 2024 at 11.59pm GMT, enabling a contract to be signed from Tuesday 17th December 2024."
},
"awards": [
{
"id": "039504-2024-GEL-SR-291-21-004-1",
"relatedLots": [
"1"
],
"title": "Whole Genome Sequencing (WGS) Long Read Instruments & Consumables",
"status": "active",
"hasSubcontracting": true,
"suppliers": [
{
"id": "GB-FTS-113896",
"name": "Oxford Nanopore Technologies PLC"
}
]
}
],
"parties": [
{
"id": "GB-FTS-130835",
"name": "Genomics England",
"identifier": {
"legalName": "Genomics England"
},
"address": {
"streetAddress": "One Canada Square, Canary Wharf",
"locality": "London",
"region": "UKI",
"postalCode": "E14 5AB",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Paul Nicholson",
"telephone": "+44 2078825030",
"email": "paul.nicholson@genomicsengland.co.uk"
},
"roles": [
"buyer"
],
"details": {
"url": "http://www.genomicsengland.co.uk",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "BODY_PUBLIC",
"description": "Body governed by public law"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
},
{
"id": "GB-FTS-113896",
"name": "Oxford Nanopore Technologies PLC",
"identifier": {
"legalName": "Oxford Nanopore Technologies PLC"
},
"address": {
"locality": "Oxford",
"region": "UKJ14",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-497",
"name": "The High Court",
"identifier": {
"legalName": "The High Court"
},
"address": {
"streetAddress": "Strand",
"locality": "London",
"postalCode": "WC2A 2LL",
"countryName": "United Kingdom"
},
"roles": [
"reviewBody"
]
}
],
"buyer": {
"id": "GB-FTS-130835",
"name": "Genomics England"
},
"contracts": [
{
"id": "039504-2024-GEL-SR-291-21-004-1",
"awardID": "039504-2024-GEL-SR-291-21-004-1",
"title": "Whole Genome Sequencing (WGS) Long Read Instruments & Consumables",
"status": "active",
"value": {
"amount": 5234229,
"currency": "GBP"
},
"dateSigned": "2024-12-06T00:00:00Z"
}
],
"language": "en"
}